Ligand Pharmaceuticals offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. See ...

Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where Street ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

At the heart of Performance Park is a new 225,000-square-foot central distribution and logistics center that expands Ritedose ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, ...

In our analysis, we have incorporated stocks under $100 that have high growth potential. Using the Finviz screener, the ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Cantor Fitzgerald analysts on Wednesday maintained their Overweight rating and $100.00 price target on Verona Pharma (NASDAQ: VRNA) stock.According to InvestingPro data, the stock currently has a ...

The price target increase follows what Jefferies described as a "robust COPD launch trajectory" for Ohtuvayre, Verona’s PDE3/4 nebulizer treatment. The medication generated $71 million in sales during ...

Inter Milan have reportedly identified Hellas Verona wingback Jackson Tchatchoua as a potential backup option for Denzel Dumfries. Per DAZN journalist Orazio Accomando via FCInter1908, the 23-year ...